Cartilage Restoration denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for cartilage restoration are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Cartilage Restoration as Not FDA-Approved

Blue Cross Blue Shield plans routinely flag cartilage restoration procedures — including cell-based and tissue-engineering approaches — under a "not FDA-approved" or "lacks regulatory clearance" denial when the specific product or procedural technique has received FDA clearance for one indication but is being used in a manner or population that BCBS characterizes as outside that cleared scope. The denial may also appear when a plan's coverage policy treats a particular technique as investigational regardless of its current regulatory status. This is a highly appealable denial because FDA clearance and insurance coverage are separate legal questions, and many cartilage restoration techniques have well-established regulatory pathways.

## Why This Denial Is Appealable

FDA clearance or approval status is a factual, verifiable matter of public record. If the procedure or device your surgeon is recommending holds FDA 510(k) clearance, Premarket Approval (PMA), or Biologics License Application (BLA) approval, that directly refutes the stated denial reason. Your appeal should document the exact regulatory status from the FDA's public device or drug database and attach that record. If BCBS's denial letter cites a specific policy number, request a copy of the underlying medical policy for review.

## Federal Appeal Framework

• Internal appeal: You have the right to a full-and-fair internal review under ERISA §503 (employer plans) or state insurance law. File within the deadline stated in your denial letter, typically 180 days.
• External review: Under ACA §2719 and its implementing regulations, you have the right to an independent external review by an accredited Independent Review Organization (IRO) after exhausting internal appeals — generally within four months of the final internal denial.
• Expedited review: If your condition is urgent, request expedited external review simultaneously with your internal appeal. Decisions are typically rendered within 72 hours.

## Documentation to Gather

• FDA regulatory record: Pull the exact clearance or approval record from the FDA website (510(k) database, PMA database, or Drugs@FDA) for the specific product your surgeon is recommending and attach it as Exhibit A.
• Diagnosis confirmation: Operative reports, MRI imaging with radiologist interpretation, and clinic notes documenting the cartilage defect location, size, and grade.
• Prior-treatment history: A chronological list of all conservative and surgical treatments attempted, with dates and outcomes.
• Prescriber medical-necessity letter: Your orthopedic surgeon should state why this specific technique is medically necessary for your documented defect and why alternatives are insufficient.
• Clinical guidelines: Ask your surgeon to cite the applicable orthopaedic society guideline (e.g., the relevant American Academy of Orthopaedic Surgeons clinical practice guideline) supporting the approach.

## Criteria-Mapping Structure

Request BCBS's full medical necessity and coverage policy for cartilage restoration. Create a two-column table: left column lists each requirement stated in the policy; right column cites the specific chart note, imaging report, or operative finding that satisfies it. If the denial hinges solely on regulatory status, your FDA record exhibit typically resolves the dispute without needing to satisfy additional clinical criteria. Submit that table as part of your appeal letter so the reviewer can match each requirement to evidence without ambiguity.